These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 26124369)

  • 21. Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.
    Coldman AJ; Phillips N; Pickles TA
    CMAJ; 2003 Jan; 168(1):31-5. PubMed ID: 12515782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Systems Medicine Approaches to Improving Understanding, Treatment, and Clinical Management of Neuroendocrine Prostate Cancer.
    Yadav KK; Shameer K; Readhead B; Yadav SS; Li L; Kasarskis A; Tewari AK; Dudley JT
    Curr Pharm Des; 2016; 22(34):5234-5248. PubMed ID: 27174811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term survival rates of patients with prostate cancer in the prostate-specific antigen screening era: population-based estimates for the year 2000 by period analysis.
    Brenner H; Arndt V
    J Clin Oncol; 2005 Jan; 23(3):441-7. PubMed ID: 15572727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression of mean age and mean expected mortality rate by duration of follow up in cohorts with a wide range of age.
    Singer RB
    J Insur Med; 2006; 38(3):181-91. PubMed ID: 17076138
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Marital status and prostate cancer outcomes.
    Tyson MD; Andrews PE; Etzioni DA; Ferrigni RG; Humphreys MR; Swanson SK; Castle EK
    Can J Urol; 2013 Apr; 20(2):6702-6. PubMed ID: 23587510
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection.
    Brawley OW
    Cancer; 1997 Nov; 80(9):1857-63. PubMed ID: 9351560
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The relative impact and future burden of prostate cancer in the United States.
    Chan JM; Jou RM; Carroll PR
    J Urol; 2004 Nov; 172(5 Pt 2):S13-6; discussion S17. PubMed ID: 15535436
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decline in prostate cancer mortality from 1980 to 1997, and an update on incidence trends in Olmsted County, Minnesota.
    Roberts RO; Bergstralh EJ; Katusic SK; Lieber MM; Jacobsen SJ
    J Urol; 1999 Feb; 161(2):529-33. PubMed ID: 9915441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The diminishing role of transurethral resection of the prostate.
    Merrill RM; Hunter BD
    Ann Surg Oncol; 2010 May; 17(5):1422-8. PubMed ID: 20091426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuroendocrine Prostate Cancer (NEPC) progressing from conventional prostatic adenocarcinoma: factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis.
    Wang HT; Yao YH; Li BG; Tang Y; Chang JW; Zhang J
    J Clin Oncol; 2014 Oct; 32(30):3383-90. PubMed ID: 25225419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Actionable and Druggable Protein Kinases Drive the Progression of Neuroendocrine Prostate Cancer.
    Lu C; Qie Y; Liu S; Wu C; Zhang Z; Liu R; Yang K; Hu H; Xu Y
    DNA Cell Biol; 2018 Sep; 37(9):758-766. PubMed ID: 29969286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tongue and tonsil carcinoma: increasing trends in the U.S. population ages 20-44 years.
    Shiboski CH; Schmidt BL; Jordan RC
    Cancer; 2005 May; 103(9):1843-9. PubMed ID: 15772957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in survival of patients diagnosed with male genital cancers in the Nordic countries 1964-2003 followed up until the end of 2006.
    Bray F; Klint A; Gislum M; Hakulinen T; Engholm G; Tryggvadóttir L; Storm HH
    Acta Oncol; 2010 Jun; 49(5):644-54. PubMed ID: 20151937
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Neuroendocrine prostate cancer].
    Tritschler S; Erdelkamp R; Stief C; Hentrich M
    Pathologe; 2018 Jul; 39(4):333-343. PubMed ID: 29946852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The significance of changing trends in prostate cancer incidence and mortality.
    Krongrad A; Lai S; Vidal EM
    Semin Urol Oncol; 1998 Feb; 16(1):30-4. PubMed ID: 9508080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trends in mortality rates in patients with prostate cancer during the era of prostate specific antigen screening.
    Merrill RM; Stephenson RA
    J Urol; 2000 Feb; 163(2):503-10. PubMed ID: 10647666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quebec prostate cancer mortality dropped in 1996.
    Meyer F; Moore L; Bairati I; Fradet Y
    Cancer Prev Control; 1998 Aug; 2(4):163-6. PubMed ID: 10093628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.
    Shui X; Xu R; Zhang C; Meng H; Zhao J; Shi C
    Lab Invest; 2022 Apr; 102(4):332-340. PubMed ID: 34937865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Descriptive epidemiology of selected olfactory tumors.
    Villano JL; Bressler L; Propp JM; Valyi-Nagy T; Martin IK; Dolecek TA; McCarthy BJ
    J Neurooncol; 2010 Oct; 100(1):73-80. PubMed ID: 20151173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of recent trends in prostate cancer incidence and mortality.
    Dennis LK; Resnick MI
    Prostate; 2000 Mar; 42(4):247-52. PubMed ID: 10679753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.